Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2017

View Archived Issues

AG-348 well tolerated in updated data from phase II DRIVE PK study

WHSC1 revealed as a promising therapeutic target for ALL

Characterization of next-generation anti-CD19 half-life extended BiTE antibody

TP-0903 demonstrates promising in vitro and in vivo activity

NuCana BioMed patents adenosine derivatives for cancer

RedHill Biopharma begins phase IIa study of Yeliva in cholangiocarcinoma

FGFR inhibitors reported in Shanghai Allist Pharmaceutical patent

Enlibrium describes biguanide derivatives

Phase II study of anabasum in SLE begins

Arrowhead Pharmaceuticals seeks approval for phase I/II study of HBV drug

FDA issues complete response letter for Agile's Twirla

Mallinckrodt to acquire Sucampo Pharmaceuticals

FDA grants fast track designation for VAL-083 in recurrent glioblastoma

FDA updates Tasigna label to include information on stopping therapy in certain CML patients

Ono submits supplemental application for Opdivo in Japan

Poxel and Sumitomo Dainippon Pharma initiate phase III program for imeglimin

Arno Therapeutics sells remaining assets

Soliris approved in Japan for the treatment of patients with generalized myasthenia gravis

CG-806 receives orphan drug designation from FDA for treatment of AML

FDA grants fast track designation to cannabidiol oral solution for Prader-Willi syndrome

Agios submits NDA for ivosidenib to treat relapsed/refractory AML with an IDH1 mutation

Portola Pharmaceuticals provides update on BLA for AndexXa

Summit acquires Discuva and obtains innovative antibiotic discovery and development platform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...